Related Experiment Video
Updated: Aug 11, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Expectant management of localized prostatic cancer
W F Whitmore1, J A Warner, I M Thompson
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Cancer
|February 25, 1991
Summary
This study reviewed 75 patients with clinical Stage B prostate cancer. It found varied progression and survival rates, highlighting the diverse clinical course of this disease.
Area of Science:
- Urology
- Oncology
- Medical Research
Background:
- Clinical Stage B prostate cancer represents a significant patient cohort.
- Understanding the natural history of untreated Stage B prostate cancer is crucial for management.
- Long-term data on progression and survival are essential for evidence-based treatment strategies.
Purpose of the Study:
- To retrospectively analyze the clinical course of patients with histologically proven Stage B prostate cancer.
- To evaluate local progression, distant metastasis, and survival rates based on substages (B1, B2, B3).
- To characterize the varied and potentially protracted outcomes in this patient group.
Main Methods:
- Retrospective review of 75 patients with clinical Stage B prostate cancer.
- Analysis of data from patients with no therapy for at least 1 year post-diagnosis.
- Stratification by lesion substage (B1, B2, B3) and assessment of progression and survival.
Main Results:
- Local progression was the initial event in 95% of B1, 90% of B2, and 100% of B3 lesions.
- Distant metastasis occurred in 21% of B1, 46% of B2, and 22% of B3 tumors.
- 15-year actuarial survival rates were 67% (B1), 39% (B2), and 63% (B3).
Conclusions:
- Clinical Stage B prostate cancer exhibits a highly variable clinical course.
- Progression patterns and survival differ significantly across B1, B2, and B3 substages.
- These findings underscore the need for individualized monitoring and treatment approaches.
